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INTRODUCTION
Stem cells represent populations of cells that can give rise
to all kinds of tissue types necessary to constitute an organ.
Traditional understandings on stem cells were mainly derived
from hematopoietic stem cells in the model where aplastic
bone marrow cells damaged by destructive radiation was re-
populated using bone marrow transplantation (1). Over the
last decades, studies on this cell population, namely hemato-
poietic stem cells have revealed much of unique properties
not found in other cell types, such as self-renewal division, a
mitotic division leading to a production of same stem cells,
or asymmetric division, a unique division leading to un-equal
production of daughter cells from same mother cells (2).
Although the regulatory mechanisms controlling the self-
renewing process or asymmetric division might have the key
to more efficient use of stem cell in expansion culture or gene-
tic modification, they still remain largely unknown await-
ing further research. Another characteristic of stem cells in-
ferred from hematopoietic stem cell is their extensive hetero-
geneity even after the highest purification process that cur-
rently available. The most important character of these stem
cells, however, is their life-long reconstitutive activity as de-
monstrated by the long-term repopulating ability in animal
transplantation model and specific cultures designed for in
vitro assay (3). While the regulatory mechanisms for hema-
topoietic stem cells have been under active investigation,
unexpected breakthroughs were made in other aspects of stem
cell biology. One is the finding that adult hematopoietic stem
cells give rise to many other tissue type in addition to blood
cells, such as neuronal or muscle cells. Similar surprising find-
ings continue to unveil the previously hidden pluripotency
of adult stem. A series of these new findings in stem cell dif-
ferentiation initially provoked a big chaos in the classical con-
cept of cell development and differentiation. New concepts
of retro-differentiation, plasticity in differentiation, and exis-
tence of very primitive pluripotent stem cells are emerging.
Furthermore, a novel issue on stem cell identity has been ad-
dressed as to whether stem cells exist as a distinct clone in
each organ and maintained throughout the development (clon-
al nature) or they are rather product of organ function to main-
tain integrity of each organ (functional nature) (4). 
Another breakthrough in the stem cell area is the success
in establishing human embryonic stem cells (5), which has
triggered a vigorous debate between ethics and scientific merit
of their use. Human embryonic stem cells can give rise to a
greater numbers of tissue type from single cell nature (6-12)
and continue to self-renew to the extent that adult stem cells
can never achieve. Despite these attractive features in embry-
onic stem cells, still many hurdles ahead before clinical use
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Three-Dimensional Approach to Stem Cell Therapy
Recent progress in stem cell research is opening a new hope for cell therapy in
regenerative medicine. Two breakthroughs were made in the stem cell era, one,
new discoveries in multipotentiality of adult stem cells beyond the traditionally
appreciated extent, and the other, establishment of pluripotent stem cell from
human embryo. In addition to the newly identified multipotentiality of adult stem
cells, their ability to be trans-differentiated toward other tissue types (stem cell
plasticity) as well as to migrate toward the site of tissue damage make adult stem
cells particularly attractive choice for stem cell based therapy. Stem cell therapy
for organ regeneration, therefore, could be approached from three distinct dimen-
sions: first, direct differentiation of multi-potent stem cells toward desired tissue
types; secondly, regeneration of specific tissues through in vivo stem cell plas-
ticity, and lastly, by tissue-specific stem cells from many types of organs. While
each approach in stem cell therapy poses distinctive limitations for their success-
ful clinical applications, understanding regulatory mechanisms of stem cell self-
renewal and their in vivo engraftment will mostly extend their medical efficacy of
stem cell based therapy. 
Key Words : Stem Cells; Tissue Therapy; Stem Cell Therapy; Multipotentiality; Plasticity; Tissue Spe-
cific Stem Cell
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Fig. 1. Multipotentiality of bone marrow stem cell at  single cell level.
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such as immune rejection by difference in histocompatibili-
ty between donor and recipients, possible tumor formation
after in vivo transplantation, and problem of potential inap-
propriate/improper differentiation. While embryonic stem
cells are at an emerging stage in the avenue of cell therapy,
adult stem cells have been intensively used for hematological
and cancer-related managements in clinical practice. Further-
more, recent studies are still expanding their use in many clin-
ical situations that previously thought unrelated, such as me-
tabolic diseases, bone diseases, or autoimmune diseases. There-
fore, this review, focusing on stem cell-based cell therapy, will
address discussions mostly to adult stem cells, rather than
covering both types of stem cells, which should be beyond
the current extent of scope.
MULTIPOTENTIALITY OF ADULT STEM CELLS
It has been a general concept that adult stem cells, in con-
trast to embryo-derived stem cells that have a totipotent dif-
ferentiation potential, are limited in their cell types that can
be derived from a given source of adult stem cells. In addi-
tion, it has been well accepted that this limitation is princi-
pally determined by their developmental origin, in such a
way that the ectoderm-derived cells give rise to cells of ecto-
dermal origin and those from the mesoderm give rise to cells
of mesodermal origin. Furthermore, the developmental pro-
cess has been thought to be irreversible process associated
with lineage determination. However, series of new discov-
eries prompted the change of these classical concept await-
ing emerge of new concept for cell development. In 1998,
Geiger et al. (13) performed an experiment as to whether the
adult cell would become like embryonic cells in a microen-
vironment that normal developmental process is occurring.
They harvested bone marrow hematopoietic stem cells derived
from transgenic mice for human beta globin gene and inject-
ed into blastocysts of developing mice. The resulting mice
demonstrated a developmental chimerism, i.e., existence of
donor-derived cells at various stages of development, includ-
ing york sac, fetal liver, and adult bone marrow. The notion
from this remarkable observation was that, given a certain
microenvironment, the adult cells could also participate in
the developmental process going backward in their develop-
mental clock. Similarly, erythrocytes derived from adult donor
did express the embryo-type hemoglobin ( -globin and  -
globin), suggesting that the gene expression program in adult
genome could be reprogrammed in fetal microenvironment
toward that in fetal genomic program. This intriguing obser-
vation of developmental plasticity of adult cells was rapidly
extended to other models of developmental plasticity to inves-
tigate the extent of plasticity that adult stem cells can have.
From early 2000, such trials brought up several remarkable
observations that adult stem cells indeed have the differen-
tiation potential beyond the developmental origin. The first
evidence was obtained injecting neuronal precursor cells into
blastocyst of developing mice (14). In this experiment, adult
transgenic mice expressing  -galactosidase (lacZ) gene pro-
vided neural progenitor cells in the form of collection of im-
mature cells, called neurosphere. After injection into blasto-
cysts, the donor-derived neurosphere was tracked for their
contribution to various types of cells. Surprisingly, the neu-
rosphere, which was of ectodermal origin, was found to con-
tribute to most of the tissues including intestine, heart, liver,
mesonephron, as well as brain and notocord. This was the first
demonstration that adult stem cells have a higher differenti-
ation potential than previously thought beyond the develop-
mental barrier, although, some criticisms were raised for pos-
sible contamination of other primitive stem cell population.
However, on May 1991, Krause et al. (15) provided even
stronger observations using single cell suspensions. In their
experiment (schematically illustrated in Fig. 1), hematopoietic
stem cells in bone marrow was purified using surface mark-
ers (CD34+ Sca-1+). The purified cells then were labeled with
a lipid membrane-binding dye, PKH26, and transplanted
into another mouse. Forty eight hours after transplantation,
the bone marrow of primary transplanted mice were harvest-
ed and the labeled cells were isolated at a single-cell level
under microscopic guidance. These single cells were inocu-
lated into blastocysts for further development of the embryo,
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muscular dystrophy (DMD), transplantation of hematopoi-
etic stem cells as well as muscle stem cells (SP cells, see below
for description) would reconstitute the dystrophin-positive
muscle cells by 10-30% when examined 12 weeks after trans-
plantation. This observation is particularly interesting in that
stem cell transplantation could be potentially used for sys-
temic delivery of therapeutic cells to broad areas of injury in
the body.
Many similar observations were made for the plasticity of
adult stem cells. In addition to the listed examples, many
other tissues such as neuronal tissue (26, 27), renal tissue (28-
30), cartilage and bone (31-33) have been shown to be derived
from in vivo transplanted bone marrow cells.
Furthermore, in most of cases, the stem cell plasticity is
bi-directional, i.e., bone marrow cells can differentiate into
other tissues, and vice versa. For example, muscle stem cells,
certain portion of hepatic tissues and neuronal tissues could
differentiate into blood etc. (14, 19-21, 25, 26, 28, 33-39)
(summarized in Fig. 2). 
TISSUE-SPECIFIC STEM CELLS
In addition to the multipotentiality of stem cells that can
give rise to various tissue types and their plasticity that can
lead to different tissue types, adult stem cells provide addi-
tional potential way of tissue regeneration, i.e., through tissue-
specific stem cells. It has been shown that many of adult or-
gans have their own stem cells that retain some multipoten-
tiality, albeit to a variable extent depending on the organ
type. These cells include those from the pancreas, neuron,
bone and cartilage, liver, skin, and even adipose tissues (sum-
marized in Fig. 3). 
It is, however, important to note that the limited ranges
of differentiation potential does not necessarily mean their
limitation for used in cell therapy. Rather, it could be a bet-
ter source for stem cell therapy if it is more committed to a
specific lineage of tissue when purity of cell type are to be
taken. 
Pancreatic stem cell
It has been known from traditional observation that the
pancreatic ductal epithelium is the source of various islet-asso-
ciated endocrine cell populations including alpha, beta, and
delta cells in the islets of Langhans. Therefore, the pancreat-
ic ductal epithelium has been believed to contain stem cells
responsible for pancreatic endocrine cells but to easily differ-
entiate upon in vitro culture, thereby losing the insulin-secret-
ing ability (40, 41). In 2000, Ramiya et al. and Bonner-Weir
et al. simultaneously developed series of culture method by
which pancreatic ductal stem cells can proliferate maintain-
ing their ability to differentiate into islet-progenitor cells
(IPC) and accordingly ability to differentiate into insulin-
secreting beta cells (42, 43). In these reports, the islet-pro-
ducing cells were developed from crude ductal pancreatic
epithelium and thus obtained IPCs were maintained in up
to 150 serial passages (42) retaining their ability to secrete
insulin and glucagons upon terminal differentiation in vitro.
Subsequent injection of these islet cells into the renal capsule
demonstrated that thus prepared islet cells led to neovascu-
larization in the local environment, and secrete insulin in vivo.
According to the report, the blood glucose levels of diabetic
mice (non-obese diabetic: NOD) were maintained up to 5
Fig. 2. Stem cell plasticity.
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Fig. 3. Diverse source of adult stem cells.
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Fig. 5. Identification of SP (side population) cells as stem cell source. Cells were stained with Hoechst 33342 dye and subject to UV
excitation in flowcytometer. The UV-excited Hoechst dye emits two different waves, one with >650 nm (red), and 488 nm (blue). These
two lights are split into vertically arranged independent detectors. The tail part (Hoechst dim) is formed due to dye efflux mechanism
of stem cells, which is dependent on the verapamil-sensitive efflux pump. The SP cells are, therefore, verified by loss of the same pop-
ulation by verapamil treatment.
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blood expansion, ex vivo expansion and efficient tumor purg-
ing (2). 
Purification of HSC: CD34 has been a gold standard marker
for primitive stage HSCs and many clinical applications in-
cluding tumor purging have been focused on the selective
purification of CD34+ cells. Further studies revealed that
still a major heterogeneity existed in the CD34+ population
by CD38, AC133, and Thy-1 expression (56, 57). For exam-
ple, CD34+CD38- cells are mostly enriched with most prim-
itive stage HSCs which can be read out either by long-term
in vitro culture (long-term culture initiating cells: LTC-IC)
(3) or long-term in vivo NOD/SCID (non-obese diabetic/
severe combined immune deficiency) repopulating cells (CRU:
competitive repopulating unit) (58). In contrast, CD34+
CD38+ cells are more enriched with progenitor cells restrict-
ed in their potential spectrum of lineages and in their self-
renewing potential, which are often read out either by CFU-
S12, CFU-14, or colony-forming assay in semi-solid medi-
um (59). However, recent evidence revealed that additional
populations that had been previously neglected (i.e., primi-
tive CD34- cell populations) could be engrafted in NOD/
SCID mice with low clonogenicity in long-term culture, sug-
gesting that this population could be an even more primitive
cell population (60). 
In addition to purification of HSCs by cell surface markers,
functional characteristics of HSCs using their intrinsic dye-
efflux effect were also described (61). These dye-effluxing
cell population, called side population (SP) cell, are charac-
terized by dim Hoechst 33342 staining when activated by
UV light due to verapamil-sensitive dye efflux function (Fig. 5).
The SP cells were weak in CD34 expression, and lacked most
of lineage-specific markers. Interestingly, like HSCs, multi-
potent stem cells from other tissues such as muscle and liver
shares common phenotype, suggesting that the SP cell phe-
notype might be a universal stem cell marker (62).
ONTOLOGICAL DIFFERENCE IN HSCS
HSCs have been found to exist in different forms of hema-
topoietic organs throughout the ontological difference, i.e.,
adult bone marrow, neonatal cord blood, and fetal liver. Each
stage of HSCs is characterized by differential functional char-
acteristics in terms of in vivo self-renewal capacity, in vitro
proliferation potential, and optimal growth factor require-
ment (63-65). For example, fetal liver HSCs were character-
ized by the highest in vitro proliferation potential and in vivo
self-renewing capacity, while adult bone marrow cells have
the lowest position in both terms, and umbilical cord blood
is in the intermediate position (66). The basis for these func-
tional differences among ontologically different populations
remains unknown. Previously we have performed a series of
gene expression studies to investigate the distinct gene expres-
sion patterns among different stages of ontology (67). We
found that series of gene expression pattern is conserved dur-
ing in vivo differentiation from CD34+CD38- cells to CD34+
CD38+ cells and during in vitro differentiation mediated by
growth factor stimulation. Interestingly, similar difference
was also conserved during ontology-related differences in gene
expression in such a way that the gene expression pattern in
ontologically earlier stage HSC is more close to the patterns
in growth factor-stimulated cells. These findings led us to
speculate that there is a certain stage of HSC activation com-
mon to in vitro stimulation and in vivo activation called
“priming” and according to this hypothesis, fetal liver and
umbilical cord blood HSC mimic the state already growth
factor-stimulated and primed in the activation process, when
compared to adult bone marrow stem cells (schematically
illustrated in Fig. 6).158 I.-H. Oh, D.-W. Kim
the stem cell plasticity, which can regenerate many tissues
using different types of stem cells. The problem of this ap-
proach is that we can not answer such questions as  ‘what is
the controlling mechanisms?’ or ‘how does this process oc-
cur?’ To be useful for cell therapy, these phenomenological
descriptions of plasticity should be further dissected into the
regulatory mechanisms so that the efficiency of organ regen-
eration by the process could reach a therapeutic level.
The third dimension of stem cell therapy would be through
tissue-specific stem cells, such as pancreatic stem cells, hema-
topoietic stem cells for lympho-myeloid reconstitution, or
liver stem cells. The advantage of the tissue-specific stem
cells is that it can produce a highly homogenous population
of the differentiated cells unlike pluripotent embryonic stem
cells, where the possibility of improper or inappropriate dif-
ferentiation remains to be cleared. Again, however, the major
obstacle of this approach is that the cell number is limited for
a medically effective cell therapeutic dose. 
Therefore, molecular mechanisms for the expansion of adult
stem cells and differentiation of pluripotent stem cells should
be elucidated before major benefit from stem cell therapy is
envisioned.
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